Welcome to our dedicated page for QUEST DIAGNOSTICS SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics director Vicky B. Gregg increased her direct holdings through a dividend reinvestment plan. On April 20, 2026, she acquired 68 shares of Quest Diagnostics common stock at $194.698 per share via a broker-administered dividend reinvestment program. Following this automatic acquisition, she directly owns 17,172 shares of common stock. The filing notes this dividend reinvestment transaction was eligible for deferred reporting on Form 5, but she chose to report it early on Form 4.
Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 7 shares of common stock at $194.699 per share, bringing his direct holdings to 2,711 shares.
The shares were acquired automatically under a broker-administered dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6. Carter chose to report this routine transaction early on Form 4.
Quest Diagnostics director Wright Lassiter III reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 6 shares of common stock at $194.699 per share, bringing his direct holdings to 9,063 shares after the transaction. The filing notes this dividend reinvestment transaction is eligible for deferred reporting under Rule 16a-6, but the director chose to report it early on Form 4.
Quest Diagnostics SVP Karthik Kuppusamy reported a small acquisition of 39 shares of common stock at $194.699 per share. The filing describes this as a small acquisition under Rule 16a-6 related to a dividend reinvestment plan. Following the transaction, he holds 13,490 shares directly, plus indirect holdings through a trust and the company’s 401(k) plan.
Quest Diagnostics senior executive Mark E. Delaney reported a small automatic share acquisition. On April 20, 2026, he acquired 37 shares of Quest Diagnostics common stock at $194.696 per share through a dividend reinvestment plan under Rule 16a-6. Following this transaction, he directly holds 11,901 common shares.
Quest Diagnostics grew solidly in early 2026. Net revenues for the quarter ended March 31, 2026 rose to $2,895 million from $2,652 million, driven mainly by its core diagnostic information services business.
DIS revenue increased 9.4% to $2,832 million as requisition volume grew 10.9%, helped by new relationships with Corewell Health and Fresenius Medical Care. Revenue per requisition fell 1.3% due to a higher mix of routine testing, but excluding these contracts it increased about 2.5%.
Net income attributable to Quest Diagnostics rose to $252 million from $220 million, and diluted EPS increased to $2.24 from $1.94. Operating income improved to $399 million from $346 million as cost savings from the Invigorate program helped offset higher compensation and supplies. Operating cash flow was $278 million versus $314 million, reflecting timing of receipts and higher bonus payments. The company invested $114 million in capital expenditures, continued a quarterly dividend of $0.86 per share, and ended the quarter with $393 million of cash and $5.2 billion of long-term debt.
Quest Diagnostics reported strong first quarter 2026 results and raised its full year 2026 outlook. Net revenues were $2.90 billion, up 9.2% from 2025, with Diagnostic Information Services revenues up 9.4%. Reported diluted EPS increased to $2.24, up 15.5%, while adjusted diluted EPS rose to $2.50, up 13.1%, reflecting improved profitability.
Operating income grew to $399 million, with adjusted operating margin edging up to 15.4% of net revenues. Cash provided by operations was $278 million, compared to $314 million a year earlier, while capital expenditures were $114 million. The company highlighted double-digit growth in Advanced Diagnostics and strong consumer-channel performance.
For full year 2026, Quest now expects net revenues of $11.78–$11.90 billion and reported diluted EPS of $9.58–$9.78. Adjusted diluted EPS is projected at $10.63–$10.83, above prior guidance, supported by solid first quarter execution and ongoing strategic initiatives.
Quest Diagnostics is asking stockholders to vote at its 2026 annual meeting on electing eleven directors, approving 2025 executive pay on an advisory basis, ratifying its auditor, and a stockholder proposal for an independent board chair.
The proxy details a pay-for-performance program where about 92% of CEO target compensation and 81% for other named executives is variable. In 2025, net revenues were $11.04B, diluted EPS was $8.75 (adjusted $9.85), and average annual incentive payouts were 116% of target, with performance shares paying out at 154% of target. The company reports 1‑, 3‑, and 5‑year total shareholder returns of 17.2%, 17.8%, and 60.7%, respectively, and highlights continued dividend growth and share repurchases.
WENTWORTH TIMOTHY C reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Timothy C. Wentworth received an award of 198 phantom stock units linked to Quest Diagnostics common stock. These units were credited on account of his elective deferral of director cash compensation under the company’s Amended and Restated Deferred Compensation Plan for Directors and will be payable in cash when his service as a director ends.
The Vanguard Group amended its Schedule 13G for Quest Diagnostics Inc. The filing states that, following an internal realignment described in the filing, The Vanguard Group reports 0 shares beneficially owned of Quest Diagnostics common stock and 0% of the class as of 03/13/2026. The amendment explains that certain subsidiaries and business divisions will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.